1 **Biomarkers**` performance in the SEPSIS-3 era

- Amanda de la Fuente^{1,2}[†] (MSc), Jaime López-Sánchez^{3†} (MD), Luis Mario Vaquero-Roncero^{2,4†} 2
- 3 (MD), María Merino García⁵ (MD), María Elisa Sánchez Barrado^{2,4} (MD), Miguel Vicente
- Sánchez-Hernández⁴ (MD), Jesús Rico-Feijoo^{2,6} (MD), Luis Muñoz-Bellvís³ (MD), Rafael 4
- 5 González de Castro⁵ (MD), Ana P. Tedim^{1,2} (PhD), Alicia Ortega^{1,2} (MLT), Omar Abdel-lah
- Fernández³ (MD), Alejandro Suárez-de-la-Rica⁸ (MD), Emilio Maseda⁹ (MD), Ignacio Trejo 6
- 7 González⁴ (MD), Geovanna Liszeth García Carrera⁴ (MD), José Miguel Marcos-Vidal⁵ (MD),
- 8 Juan Manuel Nieto Arranz³ (MD), Carmen Esteban-Velasco^{3*} (MD), César Aldecoa^{2,5*} (MD),
- 9 Jesús F Bermejo-Martin (MD)^{1, 2, 7*}
- 10 [†]These first authors contributed equally
- 11 *These last authors contributed equally
- 12

13 1. Group for Biomedical Research in Sepsis (BioSepsis). Instituto de Investigación Biomédica de

14 Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-

- 15 182, 37007 Salamanca, Spain.
- 16 2. Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES,
- 17 CB22/06/00035), Instituto de Salud Carlos III, Avenida de Monforte de Lemos, 3-5, 28029 18 Madrid, Spain.
- 19 3. Department of General and Gastrointestinal Surgery, Hospital Universitario de Salamanca,
- 20 Instituto de Investigación Biomédica de Salamanca (IBSAL) and Universidad de Salamanca,
- 21 Salamanca, Spain.
- 22 4. Anaesthesiology and Reanimation Service, Complejo Asistencial Universitario de Salamanca,
- 23 Salamanca, Spain.
- 24 5. Anaesthesiology and Reanimation Service, Complejo Asistencial Universitario de León, León,
- 25 Spain.
- 26 6. Anaesthesiology and Reanimation Service, Hospital Universitario Río Hortega, Valladolid,
- 27 Spain.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28	7. School of Medicine,	Universidad de Salamanca,	C. Alfonso X el Sabio,	s/n, 37007 Salamanca,
----	------------------------	---------------------------	------------------------	-----------------------

- 29 Spain
- 30 8. Department of Anesthesiology and Surgical Critical Care, Hospital Universitario de La
 31 Princesa, 28006 Madrid, Spain.
- 32 9. Department of Anesthesiology and Surgical Critical Care, Hospital Universitario La Paz, 28046
- 33 Madrid, Spain.
- 34
- 35 Corresponding author: Jesús F Bermejo-Martin, Group for Biomedical Research in
- 36 Sepsis (BioSepsis). Instituto de Investigación Biomédica de Salamanca, (IBSAL)
- 37 Gerencia Regional de Salud de Castilla y León, Paseo de San Vicente, 58-182, 37007
- 38 Salamanca, Spain, jfbermejo@saludcastillayleon.es, +34 983 420 400 Ext: 168836.

3

Abstract 40

41 **Objective:** the biomarkers' performance for diagnosis and severity stratification of 42 sepsis has not been properly evaluated anew using the SEPSIS-3 criteria introduced in 43 2016. We evaluated the accuracy of 21 biomarkers classically tested in sepsis research to 44 identify infection, sepsis, and septic shock in surgical patients classified using SEPSIS-3. Methods: four groups of adult surgical patients were compared: post-surgical patients 45 46 with no infection, patients with infection but no sepsis, patients with sepsis, and patients 47 with septic shock were recruited prospectively from the surgery departments and surgical ICUs from four Spanish hospital. The area under the curve (AUC) to differentiate 48 49 between groups was calculated for each biomarker.

50 Results: A total of 187 patients were recruited (50 uninfected post-surgery controls, 50 51 patients with infection, 47 with sepsis and 40 with septic shock). The AUCs indicated 52 that none of the biomarkers tested was accurate enough to differentiate those patients with 53 infection from the uninfected controls. In contrast, procalcitonin, lipocalin 2, pentraxin 3, 54 IL-15, TNF-α, IL-6, angiopoietin 2, TREM-1, D-dimer and C-reactive protein yielded AUCs > 0.80 to discriminate the patients with sepsis or septic shock from those with no 55 56 infection. C-reactive protein and IL-6 were the most accurate markers to differentiate 57 plain infection from sepsis (AUC = 0.82). Finally, our results revealed that sepsis and 58 septic shock shared similar profiles of biomarkers.

59 Conclusion: Revaluation in the "SEPSIS-3 era" identified the scenarios where 60 biomarkers do and do not provide useful information to improve the management of 61 surgical patients with infection or sepsis.

62

Keywords 63

Biomarkers, Diagnosis, Sepsis, Severity 64

4

65 Introduction

66 Identification of sepsis remains a major challenge to implement prompt treatment in 67 surgical patients suffering from this condition. Correct and quick discrimination between sepsis and surgical related inflammation allows to early implement measures aimed to 68 69 control the infection source with surgery or antibiotics (1,2). Biomarkers are a potential 70 useful tool to improve sepsis detection, complementary to clinical information and to 71 image and/or microbiological tests, but the information regarding biomarkers must be 72 provided in minutes in order to be useful (3,4). In addition, the emergence of the SEPSIS-73 3 criteria in 2016 has re-shaped sepsis diagnosis, by proposing a new definition which 74 consider sepsis just those infections causing life-threatening organ failure (5,6). While 75 the introduction of the new SEPSIS-3 criteria has impacted epidemiological studies on 76 sepsis (7–9), how SEPSIS-3 affects the performance of sepsis biomarkers has not been 77 sufficiently studied yet.

78 In this work, we profiled a large number of biomarkers classically tested in sepsis studies 79 by using a rapid microfluidics-based test, to evaluate their performance regarding 80 identification of infection, sepsis and septic shock in surgical patients.

81

82 **Methods**

83 **Study design and patients:** Adult patients (> 18 years) recruited in the first 24 hours 84 following an abdominal surgery with no infection constituted the uninfected control 85 group. Adult patients with infection, sepsis, or septic shock of abdominal source were recruited prospectively from the surgery departments and surgical intensive care units 86 87 (ICUs) of the four participating hospitals (Hospital Universitario Río Hortega de 88 Valladolid, Complejo Asistencial Universitario de Salamanca, Complejo Asistencial 89 Universitario de León and Hospital Universitario Marqués de Valdecilla de Santander),

5

90 between January 2020 and July 2022. Infection was defined according to the US Centers 91 for Disease Control and Prevention National Surveillance Definitions for Specific Types 92 of Infections (10). Sepsis and septic shock were defined using the SEPSIS-3 consensus 93 definitions (5,6). A specific standard survey was employed in the four participating 94 hospitals to collect clinical data along with results of hematological, biochemical, 95 radiological, and microbiological investigations. Healthy controls with similar age and 96 sex characteristics to the patients were recruited from the Centro de Hemoterapia y 97 Hemodonación de Castilla y León (CHEMCYL, Valladolid, Spain). 98 Biomarkers profiling: we quantified 20 biomarkers in plasma involved in different 99 biological functions using the Ella-SimplePlex TM system from Biotechnne (San Jose, 100 California, USA) as per manufacturer instructions. The biomarkers studied were the 101 following: Lipocalin-2 (LCN2), Myeloperoxidase (MPO) (Neutrophil degranulation); 102 Intercellular adhesion molecule 1 (ICAM-1), Vascular cell adhesion molecule 1 (VCAM-1), Endothelin-1 (ET-1), Angiopoietin 2 (ANGPT2), Angiopoietin 1 103 104 (ANGPT1) (Endothelial dysfunction); D-dimer, Urokinase-type plasminogen activator 105 (uPA) (Coagulation); Interleukin 6 (IL-6), Interleukin 15 (IL-15), Tumoral necrosis 106 factor α (TNF-α), Procalcitonin (PCT), Matrix metalloproteinase 7 (MMP7), Pentraxin 107 3 (PTX3), TREM-1 (Inflammation); Interleukin 10 (IL-10), Programmed Death-ligand 108 1 (PD-L1) (immunosuppression / immunomodulation), C-X-C motif chemokine ligand 109 10 (CXCL10), Interleukin 7 (IL-7) (lymphocyte biology). Serum C-reactive protein 110 (CRP) was measured by particle enhanced immunoturbidimetric assay (e501 Module 111 Analyser, Roche Diagnostics, Meylan, France); limit of detection 0.15 mg/dL. 112 Statistical analysis: Statistical analysis was performed using IBM SPSS Statistics 25.0 113 (SPSS INC, Armonk, NY, U.S.A). The level of significance was set at 0.05. For clinical 114 characteristics of the patients, differences between groups were assessed using the γ^2 test

6

for categorical variables. Differences between groups for continuous variables and protein levels were assessed with the Kruskal–Wallis test. The accuracy of protein levels to differentiate between groups of patients was studied by calculating the area under the receiver operating characteristic curve (AUC). The optimal operating point (OOP) was calculated on the curve as previously described (11).

- 120
- 121 **Results**

122 Our study involved 187 patients, 50 uninfected post-surgery controls, 50 patients with 123 infection without sepsis, 47 with sepsis and 40 with septic shock. Patients with infection 124 were significantly younger than those in the other groups. Proportion of men to women 125 were similar in all the compared groups. Patients with sepsis and septic shock had more 126 frequently hypertension and chronic cardiac disease. Septic shock patients were the most 127 severe as evidenced by their SOFA scores at admission and stayed longer at the hospital. 128 None of the patients of the surgical control group or in the infection group died during 129 hospitalization, compared with 7 out of 47 (14.9 %) patients with sepsis and 10 out of 40 130 (25 %) patients with septic shock (Table S1, Supplementary material). The Kruskall-131 Wallis test evidenced that patients with sepsis and septic shock showed higher levels of 132 PCT, LCN2, PTX3, IL-15, TNF-a, IL-6, ANGPT2, TREM-1, D-DIMER, CXCL10, 133 VCAM-1, PD-L1 and MMP7 than healthy controls, surgical controls and patients with 134 infection but no sepsis, being the levels of PCT, LCN2, PTX3 and IL-15 the highest in 135 patients with septic shock (Fig 1; Table S2, Supplementary material). 136 We next calculated the AUCs for the different biomarkers to discriminate between

136 we next calculated the AOCS for the differentiate between
137 uninfected post-surgery controls and the patients with infection, sepsis and septic shock
138 (Fig 2; Table S3, Supplementary material). This analysis revealed that none of the
139 biomarkers tested was accurate enough to differentiate patients with a plain infection from

140 post-surgery controls, yielding all AUCs < 0.80. In contrast, PCT, LCN2, PTX3, IL-15, 141 TNF- α , IL-6, ANGPT2, TREM-1, D-DIMER and CRP yielded AUCs > 0.80 to 142 discriminate those patients with sepsis or septic shock from post-surgical patients with no 143 infection (Fig 2; Table S3, Supplementary material). The corresponding OOP are shown 144 Table S4 (Supplementary material). We also evaluated the biomarkers performance to 145 stratify severity. This analysis revealed that CRP and IL-6 were good markers to 146 differentiate plain infection from sepsis, yielding both AUCs of 0.82 for this comparison 147 (Table S3, Supplementary material). The corresponding OOP are shown Table S4 148 (Supplementary material). In turn, PCT, LCN2, PTX3, IL-15, TNF-α, IL-6, ANGPT2, 149 CRP and IL-10 showed all AUCs \geq 0.80 to discriminate between infection and septic 150 shock (Table S3, Supplementary material). The corresponding OOP are shown Table S4 151 (Supplementary material). Finally, our results revealed that sepsis and septic shock shared 152 similar profiles of biomarkers, with none of them yielding AUCs > 0.80 to differentiate 153 between these two conditions (Table S3, Supplementary material).

154

155 Discussion

156 Since the introduction of the new SEPSIS-3 criteria in 2016, studies evaluating the 157 performance of biomarkers to diagnose and to stratify sepsis severity are lacking or 158 focused on a limited number of molecules (12–16). Here we evaluated 21 biomarkers 159 involved in different biological functions in sepsis (inflammation, neutrophil 160 degranulation, endothelial dysfunction, coagulation, immunosuppression and lymphocyte 161 biology), and compared their performance to discriminate between surgical patients with 162 no infection, infection with no sepsis, sepsis or septic shock, as defined by SEPSIS-3. Our results evidenced the limitations of the assessed biomarkers to differentiate those patients 163 164 with infection from those with no infection, revealing that, in absence of significant organ

8

165 failure, the biological response to an infectious or to a surgical challenge is similar. While 166 these results evidence that the biomarkers tested would not be helpful to better allocate 167 antibiotic treatment in patients with suspected infection when sepsis is absent, we 168 identified in contrast a number of them (PCT, LCN2, PTX3, IL-15, TNF-a, IL-6, 169 ANGPT2, TREM-1, D-DIMER, CRP) which definitively could contribute to quickly 170 identify those patients with sepsis or septic shock and to early implement empiric therapy 171 with wide spectrum antibiotics, along with the other bundles recommended by the 172 surviving sepsis campaign (hemodynamic management, ICU admission, antimicrobial 173 therapy, implemention of any required source control intervention, ventilation and other 174 additional therapies) (17). In turn, CRP and IL-6 were also good candidates to 175 differentiate surgical patients with infection with or without sepsis. This finding is also 176 very important from a translational point of view since quantification of these biomarkers 177 is widely available in hospital settings. Finally, our study revealed that none of the 178 biomarkers evaluated was good enough to differentiate between patients with sepsis and 179 those with septic shock, revealing that both scenarios induce similar alterations in the host 180 response.

A strength of our study is that we employed a next-generation immunoassay based on microfluidics (Ella-SimplePlex) which provides biomarkers levels in less than 90 minutes, which is a reasonable frame time to provide actionable information in patients with suspected sepsis or septic shock. While the limited sample size makes this a pilot study, our results warrant further evaluation of biomarker profiling using Ella-SimplePlex in larger cohorts of patients.

187 In conclusion, our study re-approached the performance of sepsis biomarkers in the188 "SEPSIS-3 era", identifying the scenarios and molecules really adding valuable

information to improve the management of surgical patients suffering this deadly 189

- 190 condition.
- 191

192 List of abbreviations

- 193 ANGPT2: Angiopoietin 2
- 194 AUC: Area under the receiver operating characteristic curve
- 195 CXCL10: C-X-C motif chemokine ligand 10
- 196 ICAM-1: Intercellular adhesion molecule 1
- 197 ICU: Intensive care unit
- 198 IL-6: Interleukin 6
- 199 IL-7: Interleukin 7
- 200 IL-10: Interleukin 10
- 201 IL-15: Interleukin 15
- 202 MMP7: Matrix metalloproteinase 7
- 203 **OOP:** Optimal operating point
- 204 PD-L1: Programmed Death-ligand 1
- 205 **PCT:** Procalcitonin
- 206 SOFA: Sepsis related Organ Failure Assessment
- 207 TNF-α: Tumor necrosis factor α
- 208 TREM-1: Triggering receptor expressed on myeloid cells 1
- 209 uPA: Urokinase-type plasminogen activator
- 210 VCAM-1: Vascular cell adhesion molecule 1
- 211

212 Ethics approval and consent to participate: The study was approved by the respective Committees for Ethics in Clinical Research of the three participating hospitals. Methods 213 214 were carried out in accordance with current Spanish law for Biomedical Research, 215 fulfilling the standards indicated by the Declaration of Helsinki. The study was approved 216 by the Committee for Ethical Research of the coordinating institution, "Comite de Etica

11

de la Investigacion con Medicamentos del Área de Salud de Valladolid Oeste", code
PI142-19. Written informed consent was obtained from patients' relatives or their legal
representative before enrolment.

220 Consent for publication: not applicable

Availability of data and materials: The datasets generated and/or analysed during the
current study are not publicly available since they are still under elaboration for
publication by the authors but are available from the corresponding author on reasonable
request.

225 Competing interests: The authors declare that they have no competing interests

Funding: This study has been funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union: Project "PI19/00590" (JFBM), Sara Borrell program"CD018/0123" (APT) and PFIS program "FI20/00278" (AdF). The funding sources did not play any role in the design of the study and collection, analysis, interpretation of data or writing the manuscript.

Authors' contributions: JFBM designed the study. AdlF, JL, LMVR, MMG, MESB,

MVSH, JMMV, JRF, LMB, RGdC, APT, AO, ASdR, EM, CEV and CA contributed with
patient recruitment and data acquisition. AdlF and AO profiled biomarker levels in
plasma. JFBM and AdlF analyzed and interpretated of data and drafted the manuscript.
All the authors critically reviewed the article and provided final approval of the version
submitted for publication.

Acknowledgements: The authors thank the nursing teams of the participating clinical
services for their continuous support to the research programme. They also thank the
Biobanco Hospital Clínico Universitario de Salamanca, for assistance with sample
storing, and CHEMCYL (Valladolid, Spain) for providing the samples from healthy
controls.

References 242

243	1.	Brakenridge SC, Chen UI, Loftus T, Ungaro R, Dirain M, Kerr A, et al. Evaluation of a
244		Multivalent Transcriptomic Metric for Diagnosing Surgical Sepsis and Estimating Mortality
245		Among Critically Ill Patients. JAMA Netw Open. 2022 Jul 12;5(7):e2221520.

- 246 2. Jeong YK, Kim EY. Predictive Role of Changes in Presepsin and Early Sepsis in ICU Patients
- 247 After Abdominal Surgery. J Surg Res. 2022 Oct 1;278:207-15.
- 248 3. Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent JL. Biomarkers of sepsis: time 249 for a reappraisal. Crit Care. 2020 Jun 5;24(1):287.
- 250 4. Barichello T, Generoso JS, Singer M, Dal-Pizzol F. Biomarkers for sepsis: more than just 251 fever and leukocytosis—a narrative review. Crit Care. 2022 Dec;26(1):14.
- 252 Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The 5. 253 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 254 2016 Feb 23;315(8):801-10.
- 255 6. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. 256 Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the 257 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 258 2016 Feb 23;315(8):775-87.
- 259 7. Vermassen J, Decruyenaere J, De Bus L, Depuydt P, Colpaert K. Characteristics of Sepsis-2 260 septic shock patients failing to satisfy the Sepsis-3 septic shock definition: an analysis of real-261 time collected data. Ann Intensive Care. 2021 Oct 30;11(1):154.
- 262 Engoren M, Seelhammer T, Freundlich RE, Maile MD, Sigakis MJG, Schwann TA. A 8. 263 Comparison of Sepsis-2 (Systemic Inflammatory Response Syndrome Based) to Sepsis-3 264 (Sequential Organ Failure Assessment Based) Definitions-A Multicenter Retrospective 265 Study*. Crit Care Med. 2020 Sep;48(9):1258.

266	9.	Williams JM, Greenslade JH, McKenzie JV, Chu K, Brown AFT, Lipman J. Systemic
267		Inflammatory Response Syndrome, Quick Sequential Organ Function Assessment, and
268		Organ Dysfunction: Insights From a Prospective Database of ED Patients With Infection.
269		CHEST. 2017 Mar 1;151(3):586–96.

- 270 10. Centers for Disease Control and Prevention. CDC/NHSN Surveillance Definitions for
 271 Specific Types of Infections; updated 2014 [Internet]. 2022. Available from:
 272 https://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef current.pdf
- 273 11. Almansa R, Ortega A, Ávila-Alonso A, Heredia-Rodríguez M, Martín S, Benavides D, et al.
- 274 Quantification of Immune Dysregulation by Next-generation Polymerase Chain Reaction to
- Improve Sepsis Diagnosis in Surgical Patients. Ann Surg. 2019 Mar;269(3):545–53.
- 276 12. Song J, Park DW, Moon S, Cho HJ, Park JH, Seok H, et al. Diagnostic and prognostic value
 277 of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients:
 278 a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019
 279 Nov 12;19(1):968.
- 13. Song J, Moon S, Park DW, Cho HJ, Kim JY, Park J, et al. Biomarker combination and SOFA
 score for the prediction of mortality in sepsis and septic shock: A prospective observational
 study according to the Sepsis-3 definitions. Medicine (Baltimore). 2020 May
 29;99(22):e20495.
- 14. Huang N, Chen J, Wei Y, Liu Y, Yuan K, Chen J, et al. Multi-marker approach using Creactive protein, procalcitonin, neutrophil CD64 index for the prognosis of sepsis in intensive
 care unit: a retrospective cohort study. BMC Infect Dis. 2022 Jul 30;22(1):662.
- 15. Lee S, Song J, Park DW, Seok H, Ahn S, Kim J, et al. Diagnostic and prognostic value of
 presepsin and procalcitonin in non-infectious organ failure, sepsis, and septic shock: a
 prospective observational study according to the Sepsis-3 definitions. BMC Infect Dis. 2022
 Jan 4;22(1):8.

14

- 291 16. Xie Y, Zhuang D, Chen H, Zou S, Chen W, Chen Y. 28-day sepsis mortality prediction model
- from combined serial interleukin-6, lactate, and procalcitonin measurements: a retrospective
- cohort study. Eur J Clin Microbiol Infect Dis. 2023 Jan 1;42(1):77–85.
- 294 17. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving
- 295 Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock
- **296** 2021. Crit Care Med. 2021 Nov;49(11):e1063.

Tables and figures 298

- 299 Figure 1. Levels of biomarkers in healthy control, surgical control, infection, sepsis
- 300 and septic shock groups. Levels are in pg/mL. ET, endothelin; IL, Interleukin; CRP, C
- 301 reactive protein; PD-L1, programmed death-ligand 1; TNF, tumor necrosis factor;
- 302 ANGPT, angiopoietin; CXCL, chemokine ligand; MMP, matrix metalloproteinase; PCT,
- 303 procalcitonin, TREM, triggering receptor expressed on myeloid cells-1; uPA, urokinase-
- 304 type plasminogen activator; ICAM, intercellular adhesion molecule; VCAM, vascular
- 305 cell adhesion molecule; PTX, pentraxin; LCN, lipocalin; MPO, myeloperoxidase. * $P \leq$
- 306 0.050 *versus* healthy control; $\dagger P \le 0.050$ (Kruskal – Wallis test).



- Figure 2. "Big Bang" Plot. AUC to differentiate patients with infection, sepsis, and 310
- septic shock from surgical controls. ET, endothelin; IL, Interleukin; CRP, C reactive 311
- protein; PD-L1, programmed death-ligand 1; TNF, tumor necrosis factor; ANGPT, 312
- 313 angiopoietin; CXCL, chemokine ligand; MMP, matrix metalloproteinase; PCT,
- 314 procalcitonin, TREM, triggering receptor expressed on myeloid cells-1; uPA,
- urokinase-type plasminogen activator; ICAM, intercellular adhesion molecule; VCAM, 315
- 316 vascular cell adhesion molecule; PTX, pentraxin; LCN, lipocalin; MPO,
- 317 myeloperoxidase.

